ProImmune, life sciences reagents and services provider, has announced the opening on its new global headquarters building at Oasis Park, following its recent acquisition of the site.
Oasis Park, located in Eynsham, five miles outside Oxford, is a 70,000ft² business and light industrial park that currently houses six other tenants. The site offers capacity for both office accommodation and state-of-the-art laboratory facilities.
ProImmune stated that its new 18,000ft² headquarters will enable the company to expand its operational capacity and better serve its growing client base. The site will also provide the space and infrastructure needed to further advance its product portfolio, including the REVEAL Immunogenicity System – a suite of assay services designed to evaluate immune responses to vaccines and therapeutics – and the Ankyron target binding reagent platform, which addresses challenges in antibody research such as cost-effectiveness and reproducibility.
“Our new global headquarters at Oasis Park, Oxford, are a reflection of ProImmune’s commitment to scientific excellence in immunology and global one-health biology,” said Nikolai Schwabe, Chief Executive Officer of ProImmune.
“The investment into the park, and into our new flexible laboratory and office facilities, strengthens our ability to deliver world-class products and services, supporting our partners to develop safer and more effective therapies for patients around the world.”